Subtyping Primary Aldosteronism With Para-chloro-2-[18F]Fluoroethyl-etomidate

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

November 6, 2024

Primary Completion Date

October 31, 2026

Study Completion Date

May 31, 2027

Conditions
Primary Aldosteronism
Interventions
DRUG

[18F]CETO tracer

PET/CT with para-chloro-2-\[18F\]fluoroethyl-etomidate (\[18F\]CETO) has a high specificity for the steroidogenic enzymes CYP11B1 and CYP11B2, present in the adrenal cortex, and has more favourable tracer characteristics compared to \[11C\]metomidate. Results obtained with this novel tracer seem promising, but its potential value in the subtyping of PA needs to be further established.

DRUG

Dexamethasone oral

Pre-treatment of dexamethasone prior to 18F CETO PET/CT scan

PROCEDURE

Adrenal vein sampling

Adrenl vein sampling

Trial Locations (1)

9713 GZ

RECRUITING

University Medical Center Groningen, Groningen

All Listed Sponsors
lead

University Medical Center Groningen

OTHER